Brief: RegeneRx Publishes RGN-259 Phase 3 Clinical Trial Results
03/01/2023 13:25
Jan 3 (Reuters) - RegeneRx Biopharmaceuticals Inc
RGRX.PK :
* PUBLICATION OF RGN-259 PHASE 3 CLINICAL TRIAL RESULTS IN
PATIENTS WITH NEUROTROPHIC KERATOPATHY
Source text for Eikon: ID:nPnbDyVbna
Further company coverage: RGRX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RegeneRx Biopharmaceuticals
See all newsBrief: Regenerx Effects Reverse Stock Split, Terminates SEC Reporting Obligations
Brief: Regenerx Receives Stockholder Approval For Reverse Stock Split
Brief: First Patient Enrolled Into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial With Rgn-259
Brief: RegeneRx Publishes RGN-259 Phase 3 Clinical Trial Results
Brief: Regenerx Reports Topline Results Of Arise-3 Dry Eye Trial